Resistance analysis of extensively drug-resistant mycobacterium tuberculosis isolatesagainst linezolid

Abstract

Abstract: Objective To investigate the resistant characteristic of extensively drug-resistant Mycobacterium tuberculosis isolatesagainst linezolid (Lzd). Methods Ninety extensively drug-resistant Mycobacterium tuberculosis clinical isolates were collected from Beijing Chest Hospital during 2012-2014. Broth dilution micro-plate alamar blue assay (MABA) was used to detect the minimal inhibitory concentration(MIC) of isolates against Lzd. Lnz resistant genes rplC、rplDand 23S rRNA were sequenced for all the enrolled isolates. Results Total of ninety isolates were enrolled .The resistant rate to common second-line anti-tuberculosis drugs is high while only 5(5/90, 5.6%) of these isolates resistant to Lzd. Mutations at 154 locus of rplC were detected in two of the isolates, and Cys→Arg has no obvious accounting to Lzd resistance. All the strains had no mutations in rplD and 23S rRNA. Conclusion The study demonstrated that linezolid resistance and mutation were rarely among extensively drug-resistant Mycobacterium tuberculosisisolates. This drug is of great use in therapy of extensively drug-resistant tuberculosis.

Key words: Extensively drug-resistant tuberculosis, Linezolid, Microbial sensitivity tests, Multidrug resistance-associated proteins, Point Mutation

ZONG Zhao-jing, JING Wei, HUO Feng-min, SHANG Yuan-yuan, LIANG Qian, LI Yun-xu, PANG Yu, HUANG Hai-rong. Resistance analysis of extensively drug-resistant mycobacterium tuberculosis isolatesagainst linezolid[J]. Electronic Journal of Emerging Infectious Diseases, 2017, 2(3): 160-163.

References

[1] World Health Organization.Global tuberculosis report 2016[R]. Geneva:World Health Organization, 2016:5-9.
[2] World Health Organization.WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update[R]. Geneva: World Health Organization, 2016:11-14.
[3] World Health Organization.WHO Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis[R]. Geneva: WHO, 2014:7-8.
[4] Lee M, Lee J, Carroll MW, et al.Linezolid for treatment of chronic extensively drug-resistant tuberculosis[J]. N Engl J Med, 2012, 367(16):1508-1518.
[5] Ippolito JA, Kanyo ZF, Wang D, et al.Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit[J].J Med Chem, 2008, 51(12):3353-3356.
[6] Bozdogan B, Appelbaum PC.Oxazolidinones: activity, mode of action, and mechanism of resistance[J]. Int J Antimicrob Agents, 2004, 23(2):113-119.
[7] Schecter GF, Scott C, True L, et al.Linezolid in the treatment of multidrug-resistant tuberculosis[J]. Clin Infect Dis, 2010, 50(1):49-55.
[8] Long KS, Vester B.Resistance to linezolid caused by modifications at its bindingsite on the ribosome[J]. Antimicrob Agents Chemother, 2012, 56(2):603-612.
[9] Beckert P, Hillemann D, Kohl TA, et al.rplCT460C identified as a dominant mutation in linezolid-resistant Mycobacteriumtuberculosis strains[J]. Antimicrob Agents Chemother,2012,56(5):2743-2745.
[10] Hillemann D, Rüsch-Gerdes S,Richter E.In vitroselected linezolidresistant Mycobacterium tuberculosis mutants[J].Antimicrob Agents Chemother, 2008,52(2):800-801.
[11] 黄海荣,于霞,姜广路,等.利奈唑胺对分枝杆菌体外抑菌作用的初步研究[J].中华结核和呼吸杂志,2011,34(8):575-578.
[12] 姚岚,唐神结,肖和平,等.利奈唑胺治疗广泛耐药结核病的临床疗效观察[J].中华临床医师,2010,4(12):2435-2440.
[13] Moellering RC.Linezolid:the first oxazolidinone antimicrobial[J]. Ann Intern Med, 2003, 138(2):135-142.
[14] 王前,宋媛媛,王玉峰,等.158株耐多药结核分枝杆菌对利奈唑胺耐药及相关基因突变情况研究[J].中国防痨杂志,2016, 38(9):712-717.
[15] Tang S, Yao L, Hao X, et al.Efficacy, safety and tolera-bility of linezolid for the treatment of XDR-TB: a study in China[J]. Eur Respir J, 2015, 45(1):161-170.
[16] Song T, Lee M, Jeon HS, et al.Linezolid Trough Concent-rations Correlate with Mitochondrial Toxicity-Related Adverse Events in the Treatment of Chronic Extensively Drug-Resistant Tuberculosis[J]. EBioMedicine, 2015, 2(11):1627-1633.
[17] Koh WJ, Kang YR, Jeon K, et al.Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis:updated analysis of 51 patients[J]. J Antimicrob Chemother, 2012, 67(6):1503-1507.
[18] Arbex M A, Bonini E H, Kawakame P G, et al.Effectiveness and safety of imipenem/clavulanate and linezolid to treat multidrug and extensively drug-resistant tuberculosis at a referral hospital in Brazil[J]. Rev Por Pneumol, 2016, 22(6):337.
[19] Park IN,Hong SB, Oh YM,et al.Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis[J]. Antimicrob Chemother, 2006, 58(3):701.
[20] 黄海荣,于霞,姜广路,等.利奈唑胺治疗耐多药结核病的初步评价[J].中国防痨杂志,2011,33(5):275-279.
[21] Zhang X, Falagas ME, Vardakas KZ, et al.Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis.[J]. Thoracic Dis, 2015, 7(4):603-615.